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Most common breast cancer susceptibility variants have been identified 675 
through genome-wide association studies (GWASs) of predominantly estrogen 676 
receptor (ER)-positive disease1. We conducted a GWAS using 21,468 ER-677 
negative cases and 100,594 controls combined with 18,908 BRCA1 mutation 678 
carriers (9,414 with breast cancer), all of European origin. We identified 679 
independent associations at P<5x10-8 with 10 variants at nine novel loci. At 680 
P<0.05, we replicated associations with 10 of 11 variants previously reported in 681 
ER-negative or BRCA1 mutation carrier GWASs, and observed consistent 682 
associations with ER-negative disease for 105 susceptibility variants identified 683 
by other breast cancer GWASs. These 125 variants explain approximately 16% 684 
of the familial risk of this breast cancer subtype. There was high genetic 685 
correlation (0.72) between risk of ER-negative breast cancer and breast cancer 686 
risk for BRCA1 carriers. These findings will likely lead to improved risk 687 
prediction and inform further fine-mapping and functional work to better 688 
understand the biological basis of ER-negative breast cancer.  689 
GWASs have identified 107 single nucleotide polymorphisms (SNPs) that are 690 
independently associated with breast cancer risk2-32. Association studies focused on 691 
ER-negative disease, or BRCA1 mutation carriers, who are more likely to develop 692 
ER-negative disease (70-80% of cases)33, have identified 11 of these 693 
SNPs3,9,12,19,29,30. We aimed to discover additional ER-negative breast cancer 694 
susceptibility variants by performing a GWAS in women of European origin. 695 
New genotyping data were generated for 9,655 ER-negative cases and 45,494 696 
controls from 68 Breast Cancer Association Consortium (BCAC) studies and 15,566 697 
BRCA1 mutation carriers (7,784 with breast cancer) from 58 Consortium of 698 
Investigators of Modifiers of BRCA1/2 (CIMBA) studies (Supplementary Tables 1 699 
and 2) using the Illumina OncoArray beadchip, a 570K SNP custom array with 700 
genome-wide coverage34. Imputation was used to derive estimated genotypes for 701 
~21M SNPs, using the 1000 Genomes Project (Phase 3) as reference; ~11.5M of 702 
those with imputation r2>0.3 and minor allele frequency (MAF)>0.005 were included 703 
in further analyses. For BCAC data, we estimated per-allele odds ratios (ORs) using 704 
logistic regression, adjusting for country and principal components. For CIMBA data, 705 
we estimated per-allele hazard ratios (HR) using a retrospective cohort analysis 706 
framework, modelling time to breast cancer and stratifying on country, Ashkenazi 707 
Jewish origin and birth cohort35,36 (see Online Methods). These analyses were also 708 
applied to an independent set of previously generated data from other genome-wide 709 
genotyping of additional European participants in 44 BCAC studies (11,813 ER-710 
negative cases and 55,100 controls)9,12,16,20,37,38 and 54 CIMBA studies (3,342 711 
BRCA1 mutation carriers, 1,630 with breast cancer) (Supplementary Tables 1 and 712 
2). Fixed-effects meta-analysis was used to combine results across genotyping 713 
initiatives within consortia and, assuming that the OR and HR estimates approximate 714 
the same underlying relative risk, across consortia39.   715 
Results from the combined meta-analysis are summarised in Supplementary Figure 716 
1. There was minimal inflation of test statistics (lambda1000=1.004; Supplementary 717 
Figure 2). We identified 10 variants at nine novel loci that were independently 718 
associated with risk of ER-negative breast cancer at P<5x10-8 (Table 1; 719 
Supplementary Table 3; Supplementary Figures 3-10). Two independent signals 720 
were observed within 12kb at 11q22.3, for rs74911261 (MAF=0.02) and rs11374964 721 
(MAF=0.42); OR estimates and statistical significance were largely unchanged when 722 
each variant was adjusted for the other (Supplementary Table 4). The association 723 
with 8p23.3-rs66823261 was not observed for BRCA1 mutation carriers (P=0.32, P-724 
heterogeneity=0.030).   725 
For each of these 10 novel signals, we identified candidate causal SNPs 726 
analytically40,41 (see Online Methods) and combined multiple sources of in silico 727 
functional annotation from public databases42-52 to identify likely functional variants 728 
and target genes. Results are summarised in Supplementary Table 5 (including 729 
UCSC Genome Browser links; see also Supplementary Note), Figure 1 and 730 
Supplementary Figures 3-10 (data sources in Supplementary Table 6). Many 731 
candidate causal SNPs lie in predicted regulatory regions and are associated with 732 
expression of nearby genes in blood or other tissues. At 2p23, the predicted target 733 
genes include ADCY3 and NCOA1 (Supplementary Figure 3). At 6q23.1 734 
(Supplementary Figure 4), the most plausible target gene is L3MBTL353. A predicted 735 
target at 8q24.13 is FBXO32, which is expressed in ER-negative HMECs but not ER-736 
positive MCF7 breast cancer cells (Supplementary Figure 6) and has a known role in 737 
cancer cachexia54. At 11q22.3 (Figure 1), a predicted target gene of common risk-738 
associated variants is NPAT55. The rarer SNPs underlying the other 11q22.3 signal 739 
are predicted to target ATM, a known breast cancer susceptibility gene56. Three rare 740 
coding variants (MAF≤0.03) in ATM, NPAT and KDELC2, are also among the 741 
candidate causal SNPs at this locus. At 16p13, predicted target genes include 742 
ADCY9 and CREBBP (Supplementary Figure 7). At 19q12 (Supplementary Figure 743 
10), a potential target gene encodes cyclin E1 which is involved in cell cycle control 744 
and phosphorylation of NPAT57. 745 
Expression QTL associations were assessed between each candidate causal variant 746 
and genes within 1Mb using 79 ER-negative breast tumours from TCGA and 135 747 
normal breast tissue samples from METABRIC58-60. The strongest associations 748 
identified were 6q23.1-rs6569648-L3MBTL3 (P=4.3x10-6) and 18q12.1-rs12965632-749 
CDH2 (P=1.0x10-4), both in METABRIC (Supplementary Table 5). SNP rs6569648 750 
was the top cis-eQTL (of all imputed variants within 1 Mb) for L3MBTL3 while the p-751 
value for the rs12965632-CDH2 eQTL was within two orders of magnitude of the top 752 
cis-eQTLs for this gene (Supplementary Figures 11-12). 753 
For 10 of the 11 variants previously identified through GWASs of ER-negative 754 
disease or overall disease in BRCA1 mutation carriers3,9,12,18,19,30,31, or reported as 755 
more strongly associated with ER-negative breast cancer29, associations with ER-756 
negative disease were replicated (P<0.05) using OncoArray data from BCAC, which 757 
does not overlap with any of the discovery studies (Table 2). Effect sizes were 758 
generally similar to those originally reported. Using all available CIMBA data, six of 759 
these 11 variants were associated with breast cancer risk (P<0.05) for BRCA1 760 
mutation carriers (Table 2). No evidence of association was observed for 20q11-761 
rs228437812 in either BCAC or CIMBA (P≥0.46).  762 
Based on estimated ORs using BCAC data for all cases with known ER status 763 
(16,988 ER-negative; 65,275 ER-positive), all 10 new and 10 previously reported 764 
and replicated ER-negative disease susceptibility SNPs were more strongly 765 
associated with risk of ER-negative than ER-positive subtype (P-heterogeneity<0.05, 766 
except for novel hit 19p13.2-rs322144; Supplementary Table 7). Two variants 767 
(1q32.1-rs4245739 and 19p13.11-rs67397200) were not associated with ER-positive 768 
disease. For four variants (11q22.3- rs11374964, 11q22.3-rs74911261, 1q32.1-769 
rs6678914 and 2p23.2-rs4577244), the risk-associated allele for ER-negative 770 
disease was associated with reduced risk of ER-positive disease (P<0.05).  771 
For these 20 ER-negative breast cancer susceptibility SNPs, we also assessed 772 
associations by triple-negative (TN) status (negative for ER, progesterone receptor 773 
and HER2; Table 3), tumour grade (Table 4) and age at diagnosis (Supplementary 774 
Table 8) using BCAC data only. Five, including the novel susceptibility variants 775 
11q22.3-rs11374964 and 11q22.3-rs74911261, were more strongly associated with 776 
risk of both TN and higher-grade disease (P<0.05), although after adjustment for TN 777 
status, heterogeneity by grade was observed only for 11q22.3-rs74911261 and 778 
1q32.1-rs4245739 (P<0.05). For 2p23.3-rs4577244, heterogeneity was observed for 779 
grade only, while 6q25.2-rs2747652 was more strongly associated with risk of other 780 
(non-TN) ER-negative breast cancer subtypes (P<0.05). At younger ages, 781 
associations appeared to be stronger for two variants (5p15.33-rs10069690 and 782 
19p13.11-rs67397200), and weaker for one (6q25.2-rs2747652) (P<0.05).  783 
Elsewhere we report 65 novel susceptibility loci for overall breast cancer1. Three of 784 
these overlap within 500kb with the novel ER-negative disease-associated loci 785 
reported here (variants 2p23.3-rs200648189, 6q23.1-rs6569648 and 8q24.13-786 
rs17350191). We assessed associations with risk of ER-negative disease, and with 787 
risk of overall breast cancer for BRCA1 mutation carriers, for SNPs at the remaining 788 
62 loci, as well as for the 96 previously reported breast cancer susceptibility variants 789 
that were not ER-negative specific. Of these 158 SNPs, 105 were associated 790 
(P<0.05) with risk of ER-negative breast cancer, and 24 with risk for BRCA1 791 
mutation carriers (Supplementary Tables 9-10). Results for BRCA2 mutation carriers 792 
are presented in Supplementary Table 11. 793 
Pathway analysis based on mapping each SNP to the nearest gene was performed 794 
using summary association statistics from the meta-analysis of BCAC and CIMBA 795 
data combined61-64 (see Online Methods). This identified several pathways 796 
implicated in ER-negative disease (enrichment score [ES]≥0.41; Supplementary 797 
Figure 13; Supplementary Tables 12-13), including a subset that was not enriched in 798 
susceptibility to ER-positive disease (ES<0; Supplementary Table 14). One of the 799 
latter subsets was the adenylate cyclase (AC) activating pathway (ES=0.62; 800 
Supplementary Figure 14). Two of the predicted target genes for the 10 novel ER-801 
negative breast cancer susceptibility variants, based on the eQTL analysis 802 
(Supplementary Table 5), ADCY3 (P[TCGA]=6.7x10-3] and ADCY9 803 
(P[METABRIC]=1.3x10-4), are part of this pathway, and their association signals 804 
were critical to the elevated ES observed (Supplementary Figure 13). ADCY9 is 805 
stimulated by β2 adrenergic receptor (β2AR) signalling65 in ER-negative breast 806 
cancer66, which in turn drives AC-cAMP signalling, including for example mitogenic 807 
signalling through β-arrestin-Src-ERK67.  808 
 809 
To further explore the functional properties of the genome that contribute to ER-810 
negative breast cancer heritability, we conducted a partitioned heritability analysis 811 
using linkage disequilibrium (LD) score regression68. Considering 52 “baseline” 812 
genomic features, we observed the greatest enrichment for super-enhancers (2.5-813 
fold, p=2x10-7) and the H3K4me3 histone mark (2.4-fold, p=0.0005), with 33% 814 
depletion (p=0.0002) observed for repressed regions (Supplementary Table 15). No 815 
differences in enrichment for these features were observed between susceptibility to 816 
ER-negative and ER-positive breast cancer, but baseline genomic features are not 817 
specific to cell type68. The estimated correlation between ER-negative and ER-818 
positive breast cancer based on ~1M common genetic variants69,70 was 0.60 819 
(standard error [SE], 0.03) indicating that, although these two breast cancer 820 
subtypes have a shared genetic component, a substantial proportion is distinct. The 821 
estimated correlation between ER-negative disease in the general population and 822 
overall breast cancer for BRCA1 mutation carriers was 0.72 (SE, 0.11). 823 
 824 
In summary, in this study of women of European origin, we have identified 10 novel 825 
susceptibility variants for ER-negative breast cancer and replicated associations with 826 
ER-negative disease for 10 SNPs identified by previous GWASs. Most of these were 827 
not associated, or more weakly associated, with ER-positive disease, consistent with 828 
the findings from pathway and partitioned heritability analyses showing that ER-829 
negative breast cancer has a partly distinct genetic aetiology. We also observed 830 
consistent associations with ER-negative disease for a further 105 overall breast 831 
cancer susceptibility SNPs. Together, these 125 variants explain ~14% of an 832 
assumed 2-fold increased risk of developing ER-negative disease for the first degree 833 
female relatives of women affected with this subtype (the newly identified SNPs 834 
explain ~1.5%); Supplementary Table 16) and ~40% of the estimated familial risk 835 
that is attributable to all variants imputable from the Oncoarray (see Online 836 
Methods). We have also identified nine novel breast cancer susceptibility variants for 837 
BRCA1 mutation carriers and confirmed associations for a further 30 previously 838 
reported SNPs; these 39 variants explain ~8% of the variance in polygenic risk for 839 
carriers of these mutations (Supplementary Table 17). However, the lower number of 840 
BRCA1 risk-associated variants may merely be a consequence of the smaller 841 
sample size, since the genetic correlation with ER-negative breast cancer is high. 842 
These findings will likely inform improved risk prediction, both for the general 843 
population and for BRCA1 mutation carriers30,71,72. Further investigation is required 844 
for other populations of non-European origin. Fine-mapping and functional studies 845 
should lead to a better understanding of the biological basis of ER-negative breast 846 
cancer, and perhaps inform the design of more effective preventive interventions, 847 
early detection and treatments for this disease. 848 
 849 
Data availability  850 
A subset of the data that support the findings of this study will be made publically 851 
available via dbGAP (www.ncbi.nlm.nih.gov/gap, contact the corresponding author 852 
for details). The complete dataset will not be made publically available due to 853 
restraints imposed by the ethics committees of individual studies; requests for further 854 
data can be made to the corresponding author or the BCAC 855 
(http://bcac.ccge.medschl.cam.ac.uk/) and CIMBA 856 
(http://cimba.ccge.medschl.cam.ac.uk/) Data Access Coordination Committees. 857 
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Figure legends 1150 
Figure 1. Genomic region around independent ER negative risk associated 1151 
variants, 11_108345515_G_A (rs11374964) and 11_108357137_G_A 1152 
(rs74911261). One Mb region showing statistical significance of all genotyped and 1153 
imputed SNPs and positions of candidate causal variants for two independent 1154 
signals (shown below as red or blue ticks) in relation to RefSeq genes. Missense 1155 
variants are labelled with asterisks. Breast cell enhancers overlapping candidate 1156 
SNPs predicted to target nearby genes by IM-PET46 are depicted as black bars. 1157 
Chromatin interactions from ENCODE ChIA-PET in MCF7 cells overlapping 1158 
candidate variants are shaded to reflect interaction confidence scores. Epigenomic 1159 
features (derived from publicly available ChIP-seq and DNase-seq) that overlap 1160 
candidate variants are shown as red or blue segments, depending on the intersected 1161 
signal. Density tracks show the summed occurrence of ChIP-seq and DNase-seq 1162 
peak signals at each position. Roadmap Epigenomics Project chromatin state 1163 
models for HMEC and myoepithelial cells grouped into enhancer, promoter or 1164 
transcribed annotations are shown as yellow, red or green segments, respectively. 1165 
Transcript levels in MCF7 and HMEC cells are represented by histograms depicting 1166 
mean normalised RNA-seq expression. All MCF7 ChIA-PET (ENCODE) and HMEC 1167 
Hi-C47 chromatin interactions are represented by black and blue arcs, respectively. 1168 
NHGRI catalog GWAS SNPs are shown as green ticks. All Oncoarray SNPs 1169 
(genotyped or imputed) are shown as black ticks and uninterrogated, common SNPs 1170 
(dbSNP138, EUR MAF > 1%) as red ticks. Features may be examined in detail via 1171 
exploration of a custom UCSC Genome Browser session accessible via hyperlinks 1172 
within Supplementary Table 5. 1173 
 1174 
 1175 
Table 1: Ten novel loci associated with risk of estrogen receptor (ER)-negative breast cancer using meta-analysis of BCAC and 1176 
CIMBA data 1177 
 
Location 
 
SNP 
 
Chr 
 
Position Nearest gene Alleles
# 
 
BCAC ER-negative† 
 
CIMBA BRCA1 mutation carriersǂ 
 
Meta-analysis 
 
     P-value 
 
Heterogeneity 
 
  P-value¥ 
 
MAF 
 
OR (95%CI) 
 
P-value 
 
MAF 
 
HR (95%CI) 
 
P-value 
2p23.3 rs200648189   2 24739694 NCOA1 CT/C 0.19 0.94 (0.91-0.97) 4.7x10-4  0.20 0.88 (0.84-0.92) 3.3x10-7  9.7x10-9    2.0x10-2 
6q23.1 rs6569648   6 130349119 L3MBTL3 T/C 0.23 0.93 (0.90-0.95) 4.3x10-8  0.22 0.94 (0.90-0.98) 5.4x10-3  8.3x10-10 0.64 
8p23.3 rs66823261   8 170692 RPL23AP53 T/C 0.23 1.09 (1.06-1.12) 5.6x10-9  0.22 1.02 (0.98-1.07)    0.32  3.3x10-8    3.0x10-2 
8q24.13 rs17350191   8 124757661 ANXA13 C/T 0.34 1.07 (1.04-1.09) 2.0x10-8  0.34 1.08 (1.04-1.12) 1.9x10-4  1.7x10-11 0.81 
11q22.3 rs11374964  11 108345515 KDELC2 G/GA 0.42 0.94 (0.92-0.96) 3.6x10-8  0.43 0.91 (0.88-0.95) 1.3x10-6  4.1x10-13 0.26 
11q22.3 rs74911261 11 108357137 KDELC2 G/A 0.02 0.82 (0.75-0.89) 2.3x10-6  0.02 0.74 (0.65-0.84) 2.0x10-6  5.4x10-11 0.17 
16p13.3 rs11076805 16 4106788 ADCY9 C/A 0.25 0.92 (0.90-0.95) 2.2x10-8  0.25 0.96 (0.92-1.00)   0.073  1.4x10-8 0.14 
18q12.1 rs36194942 18 25401204 CDH2 A/AT 0.30 0.94 (0.91-0.96) 2.5x10-7  0.31 0.95 (0.91-0.99) 1.4x10-2  1.4x10-8 0.50 
19p13.2 rs322144 19 11423703 TSPAN16 C/G 0.47 0.95 (0.93-0.97) 2.4x10-5  0.46 0.92 (0.89-0.96) 3.7x10-5  7.4x10-9 0.23 
19q12 rs113701136 19 30277729 CCNE1 C/T 0.32 1.07 (1.04-1.09) 1.7x10-7  0.32 1.05 (1.01-1.09) 1.2x10-2  6.8x10-9 0.57 
 1178 
#More common allele listed first, minor allele second; †Combined data from 21,468 ER-negative cases and 100,594 controls of European ancestry from the Breast Cancer Association Consortium 1179 
(BCAC); ǂCombined data from 18,908 BRCA1 mutation carriers from the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA), 9,414 of whom had developed breast cancer; ¥Test for 1180 
heterogeneity in effect size for ER-negative disease and overall disease for BRCA1 mutation carriers 1181 
Chr, chromosome; MAF, minor allele frequency; OR, odds ratio per copy of the minor allele; CI, confidence interval; HR, hazard ratio per copy of the minor allele 1182 
 1183 
 1184 
  1185 
Table 2: Previously reported estrogen receptor (ER)-negative hits: replication using independent data from BCAC and combined 1186 
results using all BCAC and CIMBA data 1187 
 
 
Location 
 
 
SNP 
 
 
Chr 
 
 
Position 
 
Ref 
 
Nearest 
gene 
 
Alleles# 
 
INDEPENDENT REPLICATION  
 
ALL AVAILABLE DATA COMBINED 
 
BCAC ER-negative (OncoArray)*   
 
BCAC ER-negative†  
 
CIMBA BRCA1ǂ 
 
MAF 
 
OR (95%CI) 
 
P-value 
   
OR (95%CI) 
 
P-value 
  
HR (95%CI) 
 
P-value 
1q32.1 rs6678914   1 202187176 19 LGR6 G/A 0.41 0.94 (0.91-0.97) 1.1x10-4   0.92 (0.90-0.94) 2.6x10-12  0.98 (0.95-1.02)    0.31 
1q32.1 rs4245739   1 204518842 19 MDM4 A/C 0.26 1.12 (1.09-1.17) 9.2x10-11   1.14 (1.11-1.16) 3.1x10-23  1.09 (1.04-1.13) 7.3x10-5 
2p24.1 rs12710696   2 19320803 19 MIR4757 C/T 0.37 1.04 (1.00-1.07) 2.5x10-2   1.06 (1.04-1.09) 6.5x10-8  1.01 (0.98-1.05)    0.49 
2p23.2 rs4577244ǂ   2 29120733 30 WDR43 C/T 0.34 0.93 (0.89-0.96) 9.6x10-5   0.92 (0.90-0.95) 1.5x10-9  0.92 (0.88-0.96) 1.3x10-4 
5p15.33 rs10069690    5 1279790 9,18 TERT C/T 0.26 1.19 (1.14-1.23) 3.8x10-21   1.18 (1.15-1.21) 1.5x10-35  1.18 (1.14-1.23) 3.7x10-16 
6q25.1 rs3757322ǂ   6 151942194 29 ESR1 T/G 0.32 1.14 (1.10-1.18) 5.5x10-14   1.15 (1.12-1.18) 2.8x10-31  1.14 (1.10-1.19) 2.9x10-12 
6q25.2 rs2747652ǂ   6 152437016 29 ESR1 C/T 0.48 0.92 (0.89-0.95) 1.1x10-7   0.91 (0.89-0.93) 1.9x10-18  1.00 (0.97-1.04)    0.96 
13q22.1 rs6562760ǂ 13 73957681 30 KLF5 G/A 0.24 0.92 (0.88-0.95) 5.0x10-6   0.92 (0.90-0.95) 8.7x10-10  0.89 (0.86-0.93) 3.5x10-7 
16q12.2 rs11075995 16 53855291 19 FTO T/A 0.30 1.07 (1.03-1.11) 3.3x10-4   1.09 (1.06-1.12) 1.0x10-10  1.01 (0.97-1.06)    0.49 
19p13.11 rs67397200 19 17401404 3,31 ANKLE1 C/G 0.32 1.17 (1.13-1.21) 7.0x10-20   1.17 (1.14-1.19) 2.7x10-37  1.18 (1.14-1.23) 2.7x10-17 
20q11.21 rs2284378  20 32588095 12 RALY C/T 0.32 0.99 (0.95-1.02)    0.46   1.03 (1.01-1.06) 1.7x10-2  1.00 (0.97-1.04)    0.81 
 1188 
#More common allele listed first, minor allele second; *Includes Breast Cancer Association Consortium (BCAC) OncoArray data from 9,655 ER-negative cases and 45,494 controls cases and 1189 
controls not included in previously published studies; †Combined data from 21,468 ER-negative cases and 100,594 controls of European ancestry from BCAC, which includes overlapping samples 1190 
with previous publications for all SNPs; ǂCombined data from 18,908 BRCA1 mutation carriers from the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA), 9,414 of whom had developed 1191 
breast cancer - includes overlapping samples with previous publications for SNPs rs4577244, rs3757322, rs2747652 and rs6562760 1192 
Chr, chromosome; Ref, publication(s) in reference list in which the association was identified; MAF, minor allele frequency; OR, odds ratio per copy of the minor allele; CI, confidence interval; HR, 1193 
hazard ratio per copy of the minor allele 1194 
 1195 
  1196 
Table 3: Associations for 10 novel and 10 previously reported (and replicated) ER- 1197 
negative breast cancer susceptibility loci, by triple-negative status  1198 
(BCAC data only: ER-negative casesǂ, all controls)) 1199 
 
Location 
 
SNP 
 
Triple-negative  
 
Other ER-negative 
 
Heterogeneity 
 
P-value* 
 
OR (95%CI) 
 
P-value  
 
OR (95%CI) 
 
P-value 
Loci identified by the present study     
2p23.3 rs200648189 0.95 (0.90-1.00) 4.8x10-2  0.96 (0.91-1.03)    0.24 0.36 
6q23.1 rs6569648 0.93 (0.89-0.97) 1.4x10-3  0.93 (0.88-0.98) 5.6x10-3 0.91 
8p23.3 rs66823261 1.11 (1.05-1.16) 3.3x10-5  1.12 (1.07-1.19) 2.4x10-5 0.91 
8q24.13 rs17350191 1.07 (1.03-1.11) 7.9x10-4  1.07 (1.02-1.12) 4.0x10-3 0.67 
11q22.3 rs11374964  0.88 (0.85-0.91) 1.9x10-11  0.99 (0.95-1.04)    0.75 1.5x10-5 
11q22.3 rs74911261 0.76 (0.66-0.87) 1.1x10-4  0.98 (0.84-1.13)    0.76 3.0x10-2 
16p13.3 rs11076805 0.91 (0.87-0.96) 1.5x10-4  0.95 (0.90-1.00) 4.5x10-2 0.20 
18q12.1 rs36194942 0.93 (0.89-0.96) 2.4x10-4  0.92 (0.88-0.97) 9.9x10-4 0.94 
19p13.2 rs322144 0.94 (0.91-0.98) 5.9x10-3  0.94 (0.90-0.98) 9.7x10-3 0.68 
19q12 rs113701136 1.10 (1.06-1.15) 9.1x10-7  1.07 (1.02-1.12) 4.4x10-3 0.12 
Previously reported loci (associations replicated by the present study) 
1q32.1 rs6678914 0.94 (0.91-0.98) 2.1x10-3  0.91 (0.87-0.95) 2.0x10-5 0.45 
1q32.1 rs4245739 1.18 (1.13-1.23) 4.3x10-15  1.04 (1.00-1.10) 7.5x10-2 6.5x10-4 
2p24.1 rs12710696 1.07 (1.03-1.11) 1.1x10-3  1.04 (1.00-1.09) 6.1x10-2 0.52 
2p23.2 rs4577244 0.90 (0.86-0.94) 5.3x10-6  0.94 (0.89-0.99) 1.9x10-2 0.15 
5p15.33 rs10069690  1.28 (1.23-1.33) 2.4x10-33  1.07 (1.02-1.12) 5.4x10-3 5.6x10-8 
6q25.1 rs3757322 1.15(1.10-1.19) 4.3x10-12  1.14(1.10-1.20)  4.8x10-9 0.35 
6q25.2 rs2747652 0.93(0.89-0.96) 5.7x10-5  0.87(0.83-0.91)  2.9x10-10 9.6x10-3 
13q22.1 rs6562760 0.94 (0.90-0.98) 2.8x10-3  0.92 (0.87-0.96) 8.8x10-4 0.46 
16q12.2 rs11075995 1.06 (1.02-1.11) 6.5x10-3  1.08 (1.03-1.13) 3.1x10-3 0.81 
19p13.11 rs67397200 1.27 (1.22-1.32) 2.0x10-32  1.05 (1.01-1.10) 2.7x10-2 4.7x10-10 
 1200 ǂCombined Breast Cancer Association Consortium (BCAC) data from 6,877 triple-negative and 4,467 other ER-negative cases  1201 
and 83,700 controls; *ER-negative case-only analysis, by triple-negative status; OR, odds ratio per copy of the minor allele;  1202 
CI, confidence interval 1203 
 1204 
 1205 
  1206 
Table 4: Associations for 10 novel and 10 previously reported (and replicated) ER-negative breast cancer  1207 
susceptibility loci, by grade (BCAC data only: ER-negative casesǂ, all controls) 1208 
 
Location 
 
SNP 
 
Grade 1  
 
Grade 2  
 
Grade 3 
 
Heterogeneity 
 
P-value* 
 
OR (95%CI) 
 
P-value  
 
OR (95%CI) 
 
P-value 
  
OR (95%CI) 
 
P-value 
Loci identified by the present study        
2p23.3 rs200648189 1.11 (0.92-1.33)    0.28  0.95 (0.88-1.03)    0.23  0.96 (0.91-1.00) 6.8x10-2    0.70 
6q23.1 rs6569648 0.93 (0.79-1.09)    0.37  0.93 (0.87-0.99) 1.6x10-2  0.94 (0.91-0.98) 3.8x10-3    0.34 
8p23.3 rs66823261 1.13 (0.96-1.34)    0.14  1.12 (1.04-1.19) 1.2x10-3  1.10 (1.05-1.15) 1.3x10-5    0.11 
8q24.13 rs17350191 1.16 (1.01-1.34) 3.0x10-2  1.05 (0.99-1.11)    0.10  1.09 (1.05-1.12) 4.1x10-6    0.94 
11q22.3 rs11374964  0.91 (0.79-1.04)    0.16  0.99 (0.94-1.05)    0.85  0.93 (0.90-0.96) 1.3x10-5 3.0x10-2 
11q22.3 rs74911261 1.22 (0.81-1.84)    0.35  0.89 (0.73-1.07)    0.21  0.74 (0.65-0.85) 7.4x10-6 6.7x10-4 
16p13.3 rs11076805 0.90 (0.76-1.06)    0.21  0.93 (0.87-0.99) 3.2x10-2  0.92 (0.88-0.95) 4.5x10-5    0.71 
18q12.1 rs36194942 0.97 (0.84-1.13)    0.73  0.93 (0.88-0.99) 2.2x10-2  0.96 (0.92-0.99) 2.3x10-2    0.98 
19p13.2 rs322144 0.94 (0.81-1.08)    0.38  0.95 (0.90-1.01)    0.11  0.96 (0.93-1.00) 6.4x10-2    0.48 
19q12 rs113701136 1.02 (0.89-1.18)    0.77  1.06 (1.01-1.13) 3.0x10-2  1.10 (1.06-1.14) 2.5x10-7    0.12 
Previously reported loci (associations replicated by the present study)    
1q32.1 rs6678914 0.95 (0.83-1.09)    0.46  0.90 (0.85-0.95) 9.3x10-5  0.92 (0.89-0.95) 1.2x10-6     0.75 
1q32.1 rs4245739 1.02 (0.88-1.19)    0.75  1.05 (0.99-1.12) 8.7x10-2  1.18 (1.14-1.22) 2.5x10-18 4.3x10-5 
2p24.1 rs12710696 1.08 (0.94-1.23)    0.28  1.10 (1.04-1.16) 9.6x10-4  1.04 (1.01-1.08) 1.6x10-2    0.28 
2p23.2 rs4577244 1.02 (0.88-1.20)    0.77  0.95 (0.89-1.01) 9.4x10-2  0.90 (0.86-0.93) 1.2x10-7 4.0x10-2 
5p15.33 rs10069690  0.96 (0.83-1.12)    0.64  1.07 (1.01-1.14) 2.2x10-2  1.21 (1.17-1.26) 1.5x10-24 7.3x10-4 
6q25.1 rs3757322 1.16 (1.01-1.34)    0.04  1.13 (1.07-1.20) 7.5x10-6  1.18 (1.14-1.22) 4.5x10-20    0.16 
6q25.2 rs2747652 0.86 (0.75-0.98)    0.02  0.92 (0.87-0.97) 1.9x10-3  0.90 (0.87-0.93) 1.6x10-9    0.61 
13q22.1 rs6562760 0.98 (0.84-1.15)    0.82  0.92 (0.87-0.98) 1.4x10-2  0.91 (0.88-0.95) 1.2x10-5    0.52 
16q12.2 rs11075995 1.16 (1.00-1.35) 4.7x10-2  1.09 (1.02-1.15) 7.5x10-3  1.08 (1.04-1.13) 5.2x1028    0.42 
19p13.11 rs67397200 1.01 (0.87-1.16)    0.91  1.08 (1.02-1.14) 9.8x10-3  1.22 (1.18-1.26) 5.3x10-37 1.3x10-3 
 1209 ǂCombined Breast Cancer Association Consortium (BCAC) data from 492 grade 1, 3,243 grade 2 and 8,568 grade 3 cases and 82,347 controls; * ER-negative case-only  1210 
analysis of BCAC data, by grade (trend test, 1df); OR, odds ratio per copy of the minor allele; CI, confidence interval1211 
Online Methods 1212 
 1213 
Study subjects 1214 
Supplementary Table 1 summarises the studies from the Breast Cancer Association 1215 
Consortium (BCAC) that contributed data. The majority were case-control studies. 1216 
Sixty-eight BCAC studies participated in the ER-negative breast cancer component 1217 
of the OncoArray, contributing 9,655 cases and 45,494 controls. All studies provided 1218 
core data on disease status and age at diagnosis/observation, and the majority 1219 
provided information on clinico-pathological and lifestyle factors, which have been 1220 
curated and incorporated into the BCAC database (version 6). Estrogen receptor 1221 
status for most (~70%) cases was obtained from clinical records. After removal of 1222 
overlapping participants, genotype data were also available from eight 1223 
GWASs9,12,16,37,38 (4,480 ER-negative cases and 12,632 controls) and 40 studies 1224 
previously genotyped using the Illumina iCOGS custom array20 (7,333 ER-negative 1225 
cases and 42,468 controls).  1226 
 1227 
A total of 21,468 ER-negative cases were included in the combined analyses.  Of 1228 
those 5,793 had tumours that were also negative for progesterone receptor (PR) and 1229 
human epidermal growth factor receptor 2 (HER2) and were defined as triple-1230 
negative (TN). PR and HER2 status was also obtained predominantly from clinical 1231 
records. A further 4,217 were positive for PR or HER and were considered non-TN. 1232 
The remainder had unknown PR or HER status. All participating studies were 1233 
approved by their appropriate ethics review boards and all subjects provided 1234 
informed consent.  1235 
 1236 
Subjects included from the Consortium of Investigators of Modifiers of BRCA1/2 1237 
(CIMBA) were women of European ancestry aged 18 years or older with a 1238 
pathogenic variant in BRCA1. The majority of the participants were sampled through 1239 
cancer genetics clinics. Multiple members of the same families were included in 1240 
some instances. Fifty-eight studies from 24 countries contributed Oncoarray 1241 
genotype data. After quality control (see below) and removal of overlapping 1242 
participants with the BCAC OncoArray study, data were available on 15,566 BRCA1 1243 
mutation carriers, of whom 7,784 were affected with breast cancer (Supplementary 1244 
Table 2). We also obtained iCOGS genotype data on 3,342 BRCA1 mutation carriers 1245 
(1,630 with breast cancer) from 54 studies through CIMBA. All mutation carriers 1246 
provided written informed consent and participated under ethically approved 1247 
protocols. 1248 
 1249 
OncoArray SNP selection 1250 
Approximately 50% of the SNPs for the OncoArray were selected as a “GWAS 1251 
backbone” (Illumina HumanCore), which aimed to provide high coverage for the 1252 
majority of common variants through imputation. The remaining allocation was 1253 
selected from lists supplied by each of six disease-based consortia, together with a 1254 
seventh lists of SNPs of interest to multiple disease groups. Approximately 72k 1255 
SNPs were selected specifically for their relevance to breast cancer, based on prior 1256 
evidence of association with overall or subtype-specific disease, with breast density 1257 
or with breast tissue specific gene expression. Lists were merged, as described 1258 
previously34.  1259 
 1260 
Genotype calling and quality control 1261 
Details of the genotype calling and quality control (QC) for the iCOGS and GWAS 1262 
are described elsewhere19,20,23,30, and those for OncoArray are described in the 1263 
Supplementary Note. 1264 
 1265 
Imputation 1266 
Genotypes for ~21M SNPs were imputed for all samples using the October 2014 1267 
(Phase 3) release of the 1000 Genomes Project data as the reference panel and 1268 
Nhap=800. The iCOGS, OncoArray and six of the GWAS datasets were imputed 1269 
using a two-stage imputation approach, using SHAPEIT73 for phasing and 1270 
IMPUTEv274 for imputation. The imputation was performed in 5Mb non-overlapping 1271 
intervals. All subjects were split into subsets of ~10,000 samples, with subjects from 1272 
the same grouped in the subset. The Breast and Prostate Cancer Cohort Consortium 1273 
(BPC3) and Breast Cancer Family Registry (BCFR) GWAS performed the imputation 1274 
separately using MACH and Minimac75,76. We imputed genotypes for all SNPs that 1275 
were polymorphic (MAF>0.1%) in either European or Asian samples. For the BCAC 1276 
GWAS, data were included in the analysis for all SNPs with MAF>0.01 and 1277 
imputation r2>0.3. For iCOGS and OncoArray we included data for all SNPs with 1278 
imputation r2>0.3 and MAF>0.005.  1279 
 1280 
Statistical analyses of BCAC data 1281 
Per-allele odds ratios and standard errors were generated for the Oncoarray, iCOGS 1282 
and each GWAS, adjusting for principal components using logistic regression. The 1283 
Oncorray and iCOGS analyses were additionally adjusted for country and study, 1284 
respectively. For the OncoArray dataset, principal components analysis was 1285 
performed using data for 33,661 SNPs (which included the 2,318 markers of 1286 
continental ancestry) with a MAF≥0.05 and maximum correlation of 0.1, using 1287 
purpose-written software to allow standard calculations to be performed sufficiently 1288 
rapidly on a very large dataset (http://ccge.medschl.cam.ac.uk/software/pccalc/). We 1289 
used the first 10 principal components, as additional components did not further 1290 
reduce inflation in the test statistics. We used nine principal components for the 1291 
iCOGS and up to 10 principal components for the other GWAS, where this was 1292 
found to reduce inflation. 1293 
 1294 
OR estimates were derived using MACH for the BCFR GWAS, ProbABEL77 for the 1295 
BPC3 GWAS, SNPTEST 1296 
(https://mathgen.stats.ox.ac.uk/genetics_software/snptest/snptest.html) for the 1297 
remaining GWAS and purpose written software for the iCOGS and Oncoarray 1298 
datasets. OR estimates and standard errors were combined by a fixed effects 1299 
inverse variance meta-analysis using METAL39. This was first done across the eight 1300 
GWAS, applying genomic control, as described previously20. It was then applied 1301 
(without genomic control) to combine findings from the three BCAC genotyping 1302 
initiatives (GWAS, iCOGS, OncoArray).  1303 
 1304 
The independence of signals from two variants at 11q22.3 was by fitting the logistic 1305 
regression models described above with both variants as covariates. This was done 1306 
separately for iCOGS and OncoArray data and results for each variant combined by 1307 
meta-analysis. 1308 
 1309 
For selected SNPs we estimated per-allele ORs by ER-status using all available 1310 
BCAC data for 82,263 cases with known ER status and 87,962 controls from the 1311 
iCOGS and OncoArray studies. We also estimated the per-allele ORs by TN status 1312 
(TN versus other ER-negative subtypes) and tumour grade, using available BCAC 1313 
data for ER-negative cases and corresponding controls. Tests for heterogeneity by 1314 
subtype were derived by applying logistic regression to cases only. This was done 1315 
separately for the iCOGS and Oncoarray datasets, adjusted as before, and then 1316 
combined in a fixed-effects meta-analysis. Multinomial regression was applied to 1317 
cases only to test a linear trend for grade, with the model constrained so that the 1318 
difference between grade 1 and 3 was double that for the difference between grade 1319 
2 and 3; this method was also used to test for a linear trend with age with ordinal 1320 
values 1, 2, 3 and 4 representing ages <40, 40-49, 50-59 and ≥60, respectively. 1321 
 1322 
Statistical analyses of CIMBA data 1323 
Associations between genotypes and breast cancer risk for BRCA1 mutation carriers 1324 
were evaluated using a 1df per allele trend-test (P-trend), based on modeling the 1325 
retrospective likelihood of the observed genotypes conditional on breast cancer 1326 
phenotypes36. This was done separately for iCOGS and OncoArray data. To allow 1327 
for the non-independence among related individuals, an adjusted test statistic was 1328 
used which took into account the correlation in genotypes3. All analyses were 1329 
stratified by country of residence and, for countries where strata were sufficiently 1330 
large (USA and Canada), by Ashkenazi Jewish ancestry.  The results from the 1331 
iCOGS and OncoArray datasets were then pooled using fixed effects meta-analysis. 1332 
We repeated these analyses modelling ovarian cancer as a competing risk and 1333 
observed no substantial difference in the results obtained.  1334 
 1335 
The independence of signals from two variants at 11q22.3 was assessed using 1336 
OncoArray data only, fitting a Cox regression model with per-allele effects for both 1337 
variants, adjusting for birth cohort, stratified by country of residence and using robust 1338 
standard errors and clustered observations for relatives. This approach provides 1339 
valid significance tests of associations, although the HR estimates can be biased35.  1340 
 1341 
Meta-analysis of BCAC and CIMBA 1342 
A fixed effects meta-analysis of results from BCAC and CIMBA was conducted using 1343 
an inverse variance approach assuming fixed effects, as implemented in METAL39. 1344 
The effect estimates used were the logarithm of the per-allele hazard ratio (HR) 1345 
estimate for the association with breast cancer risk in BRCA1 mutation carriers from 1346 
CIMBA and the logarithm of the per-allele OR estimate for the association with risk of 1347 
ER-negative breast cancer based on BCAC data, both of which were assumed to 1348 
approximate the same relative risk. We assessed genomic inflation using common 1349 
(MAF>1%) GWAS backbone variants. As lambda is influenced by sample size, we 1350 
calculated lambda1000 to be comparable with other studies. 1351 
 1352 
All statistical tests conducted were two-sided. 1353 
 1354 
Definition of known hits 1355 
We identified all associations previously reported from genome-wide or candidate 1356 
analysis at a significance level P<5x10-8 for overall breast cancer, ER-negative or 1357 
ER-positive breast cancer, in BRCA1 or BRCA2 carriers, or in meta-analyses of 1358 
these categories. We included only one SNP in any 500kb interval, unless joint 1359 
analysis provided genome-wide significant evidence (conditional P<5x10-8) of more 1360 
than one independent signal. Where multiple studies reported associations in the 1361 
same region, we considered the first reported association unless a later study 1362 
identified a different variant in the same region that was more strongly associated 1363 
with breast cancer risk. One hundred and seven previously reported hits were 1364 
identified, 11 of these through GWAS of ER-negative disease or of breast cancer in 1365 
BRCA1 mutation carriers, or reported as more strongly associated with ER-negative 1366 
breast cancer. These are listed in Table 2. The other 96 previously reported hits are 1367 
listed in Supplementary Table 10. 1368 
 1369 
Definition of new hits 1370 
To search for novel loci, we assessed all SNPs excluding those within 500kb of a 1371 
known hit. This identified 206 SNPs in nine regions that were associated with 1372 
disease risk at P<5x10-8 in the meta-analysis of BCAC ER-negative breast cancer 1373 
and CIMBA BRCA1 mutation carriers. The SNP with lowest p-value from this 1374 
analysis was considered the lead SNP. No additional loci were detected from the 1375 
analysis of BCAC data only. Imputation quality, as assessed by the IMPUTE2 1376 
imputation r2 in the Oncoarray dataset, was ≥0.89 for the 10 lead SNPs reported 1377 
(Supplementary Table 3).  1378 
 1379 
Candidate causal SNPs 1380 
To define the set of potentially causal variants at each of the novel susceptibility loci, 1381 
we selected all variants with p-values within two orders of magnitude of the most 1382 
significant SNP at each of the 10 novel loci. This is approximately equivalent to 1383 
selecting variants whose posterior probability of causality is within two orders of 1384 
magnitude of the most significant SNP40,41. This approach was applied to identify 1385 
potentially causal variants for the signal given by the more frequent lead SNP at 1386 
11q22.3 (rs11374964). A similar approach was applied for the rarer lead SNP at this 1387 
locus (rs74911261), but based on p-values from analyses adjusted for rs11374964. 1388 
 1389 
Proportion of familial risk explained 1390 
The relative risk of ER-negative breast cancer for the first degree female relative of a 1391 
woman with ER-negative disease has not been estimated. We therefore assumed 1392 
that the 2-fold risk observed for overall disease also applied to ER-negative disease. 1393 
In order to estimate the proportion of this explained by the 125 variants associated 1394 
with ER-negative disease, we used minor allele frequency and OR estimates from 1395 
the OncoArray-based genotype data and applied the formula: 1396 
∑ ݌௜(1 − ݌௜௜ )(ߚ௜ଶ − ߬௜ଶ) ln	(ߣ)⁄ ), where  ݌௜ is the minor allele frequency for variant i, βi is 1397 
the log(OR) estimate for variant i, τi is the standard error of βi  and λ=2 is the 1398 
assumed overall familial relative risk. 1399 
 1400 
The corresponding estimate for the FRR due to all variants is the frailty scale 1401 
heritability, defined as ℎ௙ଶ = ∑ 2݌௜(1 − ݌௜௜ )ߛ௜ଶ	, where the sum over all variants and γi  1402 
is the true relative risk conferred by variant i, assuming a log-additive model. We first 1403 
obtained the estimated heritability based on the full set of summary estimates using 1404 
LD Score Regression68, which derives a heritability estimate on the observed scale. 1405 
We then converted this to an estimate on the fraility scale using the formula ℎ௙ଶ =1406 
ℎ௢௕௦ଶ ܲ(1 − ܲ)൘ , where P is the proportion of samples in the population that are cases.  1407 
 1408 
Proportion of polygenic risk-modifying variance explained for BRCA1 carriers.  1409 
The proportion of the variance in the polygenic frailty modifying risk in BRCA1 1410 
carriers explained by the set of associated SNPs was estimated by ∑ ln ܿ௜௜ /σ2, where 1411 
ci is the squared estimated coefficient of variation in incidences associated with 1412 
SNPi78 and σ2 is the total polygenic variance, estimated from segregation data79.  1413 
 1414 
In Silico Annotation of Candidate Causal variants  1415 
We combined multiple sources of in silico functional annotation from public 1416 
databases to help identify potential functional SNPs and target genes, based on 1417 
previous observations that breast cancer susceptibility alleles are enriched in cis-1418 
regulatory elements and alter transcriptional activity28,80-82.  The influence of 1419 
candidate causal variants on transcription factor binding sites was determined 1420 
using the ENCODE-Motifs resource43. To investigate functional elements enriched 1421 
across the region encompassing the strongest candidate causal SNPs, we 1422 
analysed chromatin biofeatures data from the Encyclopedia of DNA Elements 1423 
(ENCODE) Project42, Roadmap Epigenomics Projects44 and other data obtained 1424 
through the National Center for Biotechnology Information (NCBI) Gene Expression 1425 
Omnibus (GEO) namely: Chromatin State Segmentation by Hidden Markov Models 1426 
(chromHMM), DNase I hypersensitive and histone modifications of epigenetic 1427 
markers H3K4, H3K9, and H3K27 in Human Mammary Epithelial (HMEC) and 1428 
myoepithelial (MYO) cells, T47D and MCF7 breast cancer cells and transcription 1429 
factor ChIP-seq in a range of breast cell lines (Supplementary Table 6). To identify 1430 
the SNPs most likely to be functional we used RegulomeDB45, and to identify 1431 
putative target genes, we examined potential functional chromatin interactions 1432 
between distal and proximal regulatory transcription-factor binding sites and the 1433 
promoters at the risk regions, using Hi-C data generated in HMECs47 and 1434 
Chromatin Interaction Analysis by Paired End Tag (ChiA-PET) in MCF7 cells. This 1435 
detects genome-wide interactions brought about by, or associated with, CCCTC-1436 
binding factor (CTCF), DNA polymerase II (POL2), and Estrogen Receptor (ER), all 1437 
involved in transcriptional regulation47. Annotation of putative cis-regulatory regions 1438 
and predicted target genes used the Integrated Method for Predicting Enhancer 1439 
Targets (IM-PET)46, the “Predicting Specific Tissue Interactions of Genes and 1440 
Enhancers” (PreSTIGE) algorithm48, Hnisz51 and FANTOM49. Intersections 1441 
between candidate causal variants and regulatory elements were identified using 1442 
Galaxy, BedTools v2.24 and HaploReg v4.1, and visualised in the UCSC Genome 1443 
Browser. Publically available eQTL databases including Gene-Tissue Expression 1444 
(GTEx;50 version 6, multiple tissues) and Westra52 (blood), were queried for 1445 
candidate causal variants. 1446 
 1447 
eQTL analyses 1448 
Expression quantitative trait loci (eQTL) analyses were performed using data from 1449 
The Cancer Genome Atlas (TCGA) and Molecular Taxonomy of Breast Cancer 1450 
International Consortium (METABRIC) projects59,60. 1451 
 1452 
The TCGA eQTL analysis was based on 79 ER-negative breast tumors that had 1453 
matched gene expression, copy number, and methylation profiles together with the 1454 
corresponding germline genotypes available.  All 79 individuals were of European 1455 
ancestry as ascertained using the genotype data and the Local Ancestry in adMixed 1456 
Populations (LAMP) software package (LAMP estimate cut-off >95% European)83.  1457 
Germline genotypes were imputed into the 1000 Genomes reference panel (October 1458 
2014 release) using IMPUTE275,84.  Gene expression had been measured on the 1459 
Illumina HiSeq 2000 RNA-Seq platform (gene-level RSEM normalized counts85), 1460 
copy number estimates were derived from the Affymetrix SNP 6.0 (somatic copy 1461 
number alteration minus germline copy number variation called using the GISTIC2 1462 
algorithm86), and methylation beta values measured on the Illumina Infinium 1463 
HumanMethylation450, as previously described59. Primary TCGA eQTL analysis 1464 
focused on all potentially causal variants in the 10 new regions associated with 1465 
breast cancer risk in the meta-analysis of ER-negative cases and controls from 1466 
BCAC and BRCA1 mutation carriers from CIMBA.  We considered all genes located 1467 
up to 1 Mb on either side of each of these variants.  The effects of tumor copy 1468 
number and methylation on gene expression were first removed using a method 1469 
described previously58, and eQTL analysis was performed by linear regression as 1470 
implemented in the R package Matrix eQTL87. 1471 
 1472 
The METABRIC eQTL analysis was based on 135 normal breast tissue samples 1473 
resected from breast cancer patients of European ancestry.  Germline genotyping for 1474 
the METABRIC study was also done on the Affymetrix SNP 6.0, and ancestry 1475 
estimation and imputation for this data set was conducted as described for TCGA.  1476 
Gene expression in the METABRIC study had been measured using the Illumina 1477 
HT12 microarray platform and we used probe-level estimates.  As for TCGA, we 1478 
considered all genes in 10 regions using Matrix eQTL. 1479 
 1480 
We also performed additional eQTL analyses using the METABRIC data set for all 1481 
variants within 1 Mb of L3MBTL3 and CDH2 and the expression of these specific 1482 
genes. 1483 
 1484 
Global Genomic Enrichment Analyses 1485 
We performed stratified LD score regression analyses68 for ER- breast cancer using 1486 
the summary statistics based on the meta-analyses of OncoArray, GWAS, iCOGS 1487 
and CIMBA. We used all SNPs in the 1000 Genomes Project phase 1 v3 release 1488 
that had a minor allele frequency > 1% and an imputation quality score R2>0.3 in the 1489 
OncoArray data. LD scores were calculated using the 1000 Genomes Project Phase 1490 
1 v3 EUR panel. Further details are provided in the Supplementary Note. 1491 
 1492 
We tested the differences in functional enrichment between ER-positive and ER-1493 
negative subsets for individual features through a Wald test, using the regression 1494 
coefficients and standard errors for the two subsets based on the models described 1495 
above. Finally, we assessed the heritability due to genotyped and imputed SNPs70 1496 
and estimated the genetic correlation between ER-positive and ER-negative breast 1497 
cancer69. The genetic correlation analysis was restricted to the ~1M SNPs included 1498 
in HapMap 3.  1499 
 1500 
 1501 
Pathway Enrichment Analyses (see also the Supplementary Note) 1502 
The pathway gene set database 1503 
Human_GOBP_AllPathways_no_GO_iea_January_19_2016_symbol.gmt 1504 
(http://baderlab.org/GeneSets)61, was used for all analyses. Pathway size was 1505 
determined by the total number of genes in the pathway to which SNPs in the 1506 
imputed GWAS dataset could be mapped. To provide more biologically meaningful 1507 
results, and reduce false positives, only pathways that contained between 10 and 1508 
200 genes were considered.   1509 
 1510 
SNPs were mapped to the nearest gene within 500kb; those that were further than 1511 
500 kb away from any gene were excluded. Gene significance was calculated by 1512 
assigning the lowest p-value observed across all SNPs assigned to a gene63,64, 1513 
based on the meta-analysis of BCAC and CIMBA data described above.  1514 
 1515 
The gene set enrichment analysis (GSEA)61 algorithm, as implemented in the 1516 
GenGen package (http://gengen.openbioinformatics.org/en/latest/)62,63 was used to 1517 
perform pathway analysis. Briefly, the algorithm calculates an enrichment score (ES) 1518 
for each pathway based on a weighted Kolmogorov-Smirnov statistic62. Pathways 1519 
that have most of their genes at the top of the ranked list of genes obtain higher ES 1520 
values. 1521 
 1522 
We defined an ES threshold (ES≥0.41) to yield a true-positive rate (TPR) of 0.20 and 1523 
a false-positive rate (FPR) of 0.14, with true-positive pathways defined as those 1524 
observed with false discovery rate (FDR)<0.05 in a prior analysis carried out using 1525 
the analytic approach defined above applied to iCOGS data for ER-negative disease.  1526 
 1527 
To visualize the pathway enrichment analysis results, an enrichment map was 1528 
created using the Enrichment Map (EM) v 2.1.0 app61 in Cytoscape  v3.3088, 1529 
applying an edge-weighted force directed layout. To measure the contribution of 1530 
each gene to enriched pathways and annotate the map, we reran the pathway 1531 
enrichment analysis multiple times, each time excluding one gene. A gene was 1532 
considered to drive the enrichment if the ES dropped to zero or less (pathway 1533 
enrichment driver) after it was excluded. Pathways were grouped in the map if they 1534 
shared >70% of their genes or their enrichment was driven by a shared gene. 1535 
 1536 
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